Cytel Unveiled as OneMedNet’s Newest Alliance Partner
OneMedNet (Nasdaq: ONMD) has announced Cytel Inc. as its newest alliance partner. The partnership involves OneMedNet utilizing its iRWD™ network and platform to provide Cytel with regulatory-grade clinical data. OneMedNet's platform includes over 121 million clinical exams from more than 31 million patients across 1,400+ healthcare sites.
This collaboration will enable Cytel's customers in the biotech and pharma sectors to access ONMD's data through Cytel's Fit For Purpose Data Tool. The partnership aims to foster innovation in trial design, observational studies, and AI/ML model development, focusing on therapeutic areas such as neurologic disorders, oncology, and cardiology.
OneMedNet (Nasdaq: ONMD) ha annunciato Cytel Inc. come suo nuovo partner alleato. La partnership prevede che OneMedNet utilizzi la sua rete e piattaforma iRWD™ per fornire a Cytel dati clinici di grado regolamentare. La piattaforma di OneMedNet include oltre 121 milioni di esami clinici provenienti da più di 31 milioni di pazienti in oltre 1.400 siti sanitari.
Questa collaborazione consentirà ai clienti di Cytel nei settori biotech e pharma di accedere ai dati di ONMD attraverso il Tool per Dati Fit For Purpose di Cytel. L'obiettivo della partnership è promuovere l'innovazione nel design degli studi, negli studi osservazionali e nello sviluppo di modelli AI/ML, concentrandosi su aree terapeutiche come i disturbi neurologici, l'oncologia e la cardiologia.
OneMedNet (Nasdaq: ONMD) ha anunciado a Cytel Inc. como su nuevo socio aliado. La colaboración implica que OneMedNet utilizará su red y plataforma iRWD™ para proporcionar a Cytel datos clínicos de grado regulatorio. La plataforma de OneMedNet incluye más de 121 millones de exámenes clínicos de más de 31 millones de pacientes en más de 1,400 sitios de atención médica.
Esta colaboración permitirá a los clientes de Cytel en los sectores de biotecnología y farmacéutica acceder a los datos de ONMD a través de la herramienta Fit For Purpose Data de Cytel. La asociación tiene como objetivo fomentar la innovación en el diseño de ensayos, estudios observacionales y desarrollo de modelos de IA/ML, centrándose en áreas terapéuticas como trastornos neurológicos, oncología y cardiología.
OneMedNet (Nasdaq: ONMD)는 Cytel Inc.를 새로운 제휴 파트너로 발표했습니다. 이 파트너십은 OneMedNet이 iRWD™ 네트워크와 플랫폼을 활용하여 Cytel에 규제 적격 임상 데이터를 제공하는 것을 포함합니다. OneMedNet의 플랫폼은 1,400개 이상의 의료 현장에서 3,100만 명 이상의 환자로부터 수집된 1억 2,100만 개 이상의 임상 검사를 포함합니다.
이 협력은 생명공학 및 제약 분야의 Cytel 고객이 Cytel의 Fit For Purpose Data Tool을 통해 ONMD의 데이터에 접근할 수 있게 합니다. 파트너십의 목표는 신경 장애, 종양학 및 심장병과 같은 치료 영역에 집중하여 임상 시험 설계, 관찰 연구 및 AI/ML 모델 개발에서 혁신을 촉진하는 것입니다.
OneMedNet (Nasdaq: ONMD) a annoncé Cytel Inc. comme son nouveau partenaire d'alliance. Ce partenariat implique que OneMedNet utilise son réseau iRWD™ et sa plateforme pour fournir à Cytel des données cliniques de qualité réglementaire. La plateforme de OneMedNet comprend plus de 121 millions d'examens cliniques provenant de plus de 31 millions de patients à travers plus de 1 400 sites de santé.
Cette collaboration permettra aux clients de Cytel dans les secteurs de la biotechnologie et de la pharmacie d'accéder aux données d'ONMD via l'outil Fit For Purpose Data de Cytel. L'objectif du partenariat est de favoriser l'innovation dans la conception des essais, les études d'observation et le développement de modèles IA/ML, en mettant l'accent sur des domaines thérapeutiques tels que les troubles neurologiques, l'oncologie et la cardiologie.
OneMedNet (Nasdaq: ONMD) hat Cytel Inc. als neuen Partner in einer Allianz bekannt gegeben. Die Partnerschaft umfasst die Nutzung des iRWD™-Netzwerks und der Plattform von OneMedNet, um Cytel mit regulierungsfähigen klinischen Daten zu versorgen. Die Plattform von OneMedNet beinhaltet über 121 Millionen klinische Prüfungen von mehr als 31 Millionen Patienten an über 1.400 Gesundheitsstandorten.
Diese Zusammenarbeit wird den Kunden von Cytel in den Bereichen Biotechnologie und Pharma ermöglichen, über Cytels Fit For Purpose Data Tool auf die Daten von ONMD zuzugreifen. Das Ziel der Partnerschaft ist es, Innovationen im Studiendesign, in Beobachtungsstudien und in der Entwicklung von KI/ML-Modellen zu fördern, mit einem Fokus auf therapeutische Bereiche wie neurologische Störungen, Onkologie und Kardiologie.
- Partnership with Cytel, a global leader in clinical trial design and software
- Access to OneMedNet's extensive iRWD™ network with 121 million clinical exams from 31 million patients
- Potential for accelerated development of new medical therapies and technologies
- Expansion of OneMedNet's commercial reach in the global life science industry
- None.
The collaboration between OneMedNet and Cytel is a noteworthy development for both companies, potentially impacting their financial performance positively. OneMedNet’s access to regulatory-grade Real World Data (RWD) and Cytel’s analytics capabilities could open new revenue streams by offering enhanced data services to biotech and pharma companies. This strategic alliance can drive growth by capitalizing on the increasing demand for robust clinical trial data and advanced analytics. For investors, this partnership implies a broader market reach and enhanced service offerings, which could translate to higher earnings and improved stock performance over the long term. Additionally, the mention of top biopharmaceutical companies among Cytel's clientele underscores the potential for substantial business growth, making this a highly impactful development.
From a medical research perspective, this partnership stands to significantly enhance the quality and scope of clinical trials. OneMedNet’s extensive data repository, coupled with Cytel’s advanced analytics, can lead to more precise and efficient trial designs. The combination of clinical and imaging data will provide a richer dataset for observational studies and AI/ML model development. This can accelerate the discovery of new therapies and improve the understanding of various medical conditions. For stakeholders in the biotech and pharmaceutical industries, the enhanced data quality and analytic capabilities can reduce trial durations and costs, potentially speeding up the time-to-market for new treatments.
Technologically, this alliance symbolizes a significant leap in the use of big data and analytics in healthcare. OneMedNet’s iRWD™ platform is designed to handle vast amounts of clinical data, ensuring secure and efficient de-identification and curation. By integrating with Cytel’s Fit For Purpose Data Tool, this collaboration will leverage advanced AI/ML models to draw actionable insights from complex datasets. This technological synergy is a powerful example of how big data and advanced analytics can converge to drive innovation in the life sciences sector. Stakeholders should watch for further technological integrations that could enhance data-driven decision-making in medical research and clinical trials.
Cytel’s software products and services are utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companies
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Further to its press release dated June 14, 2024, OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (“RWD”), inclusive of electronic health records, laboratory results and, uniquely, medical imaging, announced today that Cytel Inc, (“Cytel”), a global leader in clinical trial design and software, has now identified itself as the other party with which OneMedNet recently entered into a iRWD™ Customer Data License (the “Agreement”).
Pursuant to the Agreement, OneMedNet is utilizing its proprietary iRWD™ network and platform, comprised of over 121 million clinical exams from more than 31 million patients at over 1,400 healthcare system and provider sites, to securely search, de-identify and curate current, regulatory-grade clinical data for Cytel. Combining OneMedNet’s unrivalled RWD repository with Cytel’s advanced analytics capabilities will enable customers in the biotech and pharma sectors to access ONMD’s data via Cytel’s popular Fit For Purpose Data Tool, fostering innovation in trial design, observational studies, and development of AI/ML models. The combined clinical and imaging data is specifically tailored to meet the analytics needs of sponsors across multiple therapeutic areas including neurologic disorders, oncology, and cardiology.
In a statement, Massoud Toussi, Cytel’s Vice President, Global Head of Real-World Evidence, said “As a human data science company, we’re thrilled to announce our strategic partnership with OneMedNet. Their unique access to data from imaging devices, combined with their innovative iRWD platform for collecting additional clinical data, aligns perfectly with our mission. This collaboration will empower us to deliver additional valuable solutions to our clients and drive meaningful impact in our industry.”
“This partnership aligns perfectly with OneMedNet’s market expansion strategy, and significantly extends our commercial reach within the global life science industry,” reiterated Aaron Green, OneMedNet's President and CEO. “Cytel’s recognized expertise in clinical trial design and implementation, combined with our innovative RWD platform, creates a powerful synergy that should help accelerate the development of innovative new medical therapies and technologies targeting some of the world’s greatest health challenges.”
About Cytel Inc.
Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty-five years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence, and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 1,900 resources across North America, Europe, and Asia. For more information about Cytel, please visit us at www.cytel.com.
About OneMedNet Corporation
OneMedNet provides innovative solutions that unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of a continuously expanding and diverse set of clinical data, including electronic health records, laboratory results, and uniquely, medical images. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology, and cardiology. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
OneMedNet Contacts:
Stephen Kilmer, Investor Relations
Phone: 647.872.4849
Email: stephen.kilmer@onemednet.com
Michael Wong, Director of Marketing
Phone: 800.918.7189
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
FAQ
What is the new partnership announced by OneMedNet (ONMD)?
How many clinical exams and patients does OneMedNet's (ONMD) iRWD™ platform cover?
What therapeutic areas will the OneMedNet (ONMD) and Cytel partnership focus on?
How will Cytel's customers access OneMedNet's (ONMD) data?
